These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22980311)

  • 1. Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors.
    Zhang Y; Baik SH; Chang CC; Kaplan CM; Lave JR
    Am Heart J; 2012 Sep; 164(3):425-433.e4. PubMed ID: 22980311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race/Ethnicity, disability, and medication adherence among medicare beneficiaries with heart failure.
    Zhang Y; Baik SH
    J Gen Intern Med; 2014 Apr; 29(4):602-7. PubMed ID: 24366395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.
    Lauffenburger JC; Robinson JG; Oramasionwu C; Fang G
    Circulation; 2014 Feb; 129(7):754-63. PubMed ID: 24326988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication adherence and readmission after myocardial infarction in the Medicare population.
    Zhang Y; Kaplan CM; Baik SH; Chang CC; Lave JR
    Am J Manag Care; 2014; 20(11):e498-505. PubMed ID: 25651604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age.
    Setoguchi S; Glynn RJ; Avorn J; Levin R; Winkelmayer WC
    Am J Cardiol; 2007 Oct; 100(7):1061-7. PubMed ID: 17884362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries.
    Colantonio LD; Huang L; Monda KL; Bittner V; Serban MC; Taylor B; Brown TM; Glasser SP; Muntner P; Rosenson RS
    JAMA Cardiol; 2017 Aug; 2(8):890-895. PubMed ID: 28423147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Changes in Medication Use and Adherence With Accountable Care Organization Exposure in Patients With Cardiovascular Disease or Diabetes.
    McWilliams JM; Najafzadeh M; Shrank WH; Polinski JM
    JAMA Cardiol; 2017 Sep; 2(9):1019-1023. PubMed ID: 28700790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term medication adherence after myocardial infarction: experience of a community.
    Shah ND; Dunlay SM; Ting HH; Montori VM; Thomas RJ; Wagie AE; Roger VL
    Am J Med; 2009 Oct; 122(10):961.e7-13. PubMed ID: 19560749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
    Austin PC; Tu JV; Ko DT; Alter DA
    CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full coverage for preventive medications after myocardial infarction.
    Choudhry NK; Avorn J; Glynn RJ; Antman EM; Schneeweiss S; Toscano M; Reisman L; Fernandes J; Spettell C; Lee JL; Levin R; Brennan T; Shrank WH;
    N Engl J Med; 2011 Dec; 365(22):2088-97. PubMed ID: 22080794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
    Chrischilles EA; Schneider KM; Schroeder MC; Letuchy E; Wallace RB; Robinson JG; Brooks JM
    J Am Geriatr Soc; 2016 Mar; 64(3):526-35. PubMed ID: 26928940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.
    Mathews R; Wang W; Kaltenbach LA; Thomas L; Shah RU; Ali M; Peterson ED; Wang TY
    Circulation; 2018 May; 137(20):2128-2138. PubMed ID: 29386204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
    Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
    Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK; Setoguchi S; Levin R; Winkelmayer WC; Shrank WH
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1189-96. PubMed ID: 18956426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.